5 Things to Know About a COVID Vaccine: It Won鈥檛 Be a 鈥楳agic Wand鈥
Approval of a vaccine will be an important step in defeating COVID-19. But it won鈥檛 immediately end the pandemic.
Vaccines
721 - 740 of 819 Results
-
-
These Secret Safety Panels Will Pick the COVID Vaccine Winners
Data and safety monitoring boards work under a cloak of secrecy meant to prevent undue influence by stakeholders, such as companies or the government. In the Trump era, some worry the anonymity could actually invite it.
-
Signs of an 鈥極ctober Vaccine Surprise鈥 Alarm Career Scientists
President Donald Trump has the legal power to authorize a COVID vaccine over the objections of the Food and Drug Administration and vaccine manufacturers. Such a move could further erode public trust in a vaccine and foist an unsafe shot on Americans.
By Liz Szabo and JoNel Aleccia -
KHN on the Air This Week
KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here鈥檚 a collection of their appearances.
-
COVID Vaccine Trials Move at Warp Speed, But Recruiting Black Volunteers Takes Time
The National Institutes of Health has suggested minorities should be overrepresented in COVID-19 vaccine trials 鈥 perhaps at rates that are聽double their percentage of the U.S. population. But efforts to recruit patients from racial minority groups are just beginning, while some trials have already advanced to phase 3.
-
NIH ‘Very Concerned’ About Serious Side Effect in Coronavirus Vaccine Trial
The AstraZeneca trial is on hold in the U.S. as scientists try to unravel whether a rare neurological condition is linked to the vaccine. But regulators are frustrated by a lack of information from the drugmaker.
By Arthur Allen and Liz Szabo -
Readers and Tweeters Grapple With COVID Therapies and Forecasts
Kaiser Health News gives readers a chance to comment on a recent batch of stories.
-
KHN鈥檚 鈥榃hat the Health?鈥: The Politics of Science
Republicans have all but abandoned the Affordable Care Act as a campaign cudgel, judging from their national convention, at least. Meanwhile, career scientists at the federal government鈥檚 preeminent health agencies 鈥 the Food and Drug Administration, the Centers for Disease Control and Prevention and the National Institutes of Health 鈥 are all coming under increasing political pressure as the pandemic drags on. Joanne Kenen of Politico, Mary Ellen McIntire of CQ Roll Call and Sarah Karlin-Smith of the Pink Sheet join KHN鈥檚 Julie Rovner to discuss this and more. Plus, Rovner interviews KHN鈥檚 Elizabeth Lawrence about the latest KHN-NPR 鈥淏ill of the Month鈥 installment.
-
Most Adults Wary of Taking Any Vaccine Approved Before the Election
About 60% of poll respondents are worried that federal regulators will rush to allow a vaccine because of political pressure. Opposition to getting a vaccine that might be authorized before the November election is strongest among Republicans.
By Jordan Rau -
With Schools Starting Online, Vaccinations Head for Recess
Traditionally, requirements that kids undergo certain immunizations before attending school have been a critical public health tool. Health officials are scrambling to make sure children don鈥檛 fall through the cracks.
-
As Threat of Valley Fever Grows Beyond the Southwest, Push Is On for Vaccine
Efforts are underway to bring to market a vaccine for valley fever, a fungal infection with COVID-like symptoms that occurs in the deserts of the Southwest. The illness is getting more attention as cases rise and a warming climate threatens to spread it through the West.
By Jim Robbins -
Health Officials Worry Nation’s Not Ready for COVID-19 Vaccine
As the nation awaits a vaccine to end the pandemic, local health departments say they lack the staff, money, tools 鈥 and a unified plan 鈥 to distribute, administer and track millions of vaccines, most of which will require two doses. Dozens of doctors, nurses and health officials interviewed by KHN and The Associated Press expressed their concern and frustration over federal shortcomings.
By Liz Szabo -
Fauci Says COVID Vaccine Trials Could End Early If Results Are Overwhelming
The nation鈥檚 top infectious disease official is confident that an independent panel will base vaccine approval on science, not politics.
By Liz Szabo -
Republican Convention, Day 4: Fireworks … and Shining a Light on Trump’s Claims
Donald Trump accepted his party's nomination to seek reelection for a second term as president in front of a partisan audience that appeared to largely lack masks and opt against social distancing.
-
COVID + Influenza: This Is a Good Year to Get a Flu Shot, Experts Advise
A robust sign-up for flu shots could help head off a nightmare scenario in the coming winter of hospitals stuffed with both COVID-19 patients and those suffering from severe effects of influenza. Plus, no one knows how flu and COVID might interact if a patient got both.
By Julie Appleby and Michelle Andrews -
LA Hospital Seeks Vaccine Trial Participants Among Its Own High-Risk Patients
Harbor-UCLA Medical Center serves patients who are especially vulnerable to the coronavirus: They are essential workers, have chronic diseases and are members of underrepresented racial and ethnic groups. When the safety-net hospital kicks off enrollment for its COVID-19 vaccine trial Wednesday, it will look to those patients to participate.
By Arthur Allen -
They Pledged to Donate Rights to Their COVID Vaccine, Then Sold Them to Pharma
Advocates of cheap and widely available vaccines thought the pandemic might change business as usual. They were wrong.
By Jay Hancock -
Trust, Fear and Solidarity Will Determine the Success of a COVID Vaccine
Polio terrified Americans, and in 1955, when Jonas Salk鈥檚 vaccine became available, they snapped it up like candy. Sixty-five years later, COVID is the latest dread virus, but many undercurrents could inhibit its acceptance.
By Arthur Allen -
With COVID Vaccine Trial, Rural Oregon Clinic Steps Onto World Stage
A small allergy clinic in Medford, Oregon, might seem an unlikely place to recruit hundreds of volunteers to test the Moderna vaccine against COVID-19. But its steward has a record of leading hundreds of clinical trials.
-
Test Sites Quickly Attract Thousands for COVID-19 Vaccine Study
People have flooded U.S. testing sites with requests to participate in the pivotal, late-stage clinical trials of the first two COVID-19 vaccine candidates.
By Phil Galewitz and JoNel Aleccia